Lunsumio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of non-hodgkin lymphoma, limited treatment options for relapsed follicular lymphoma, rising oncology clinical trial activity, advancement in antibody engineering techniques, regulatory approvals for novel immunotherapies.

The growth in the forecast period can be attributed to expansion of personalized cancer treatment approaches, growing adoption of immuno-oncology combinations, increasing investments in oncology biologics, rising demand for outpatient cancer therapies, continued innovation in bispecific antibody platforms. Major trends in the forecast period include increasing adoption of bispecific antibody therapies, rising focus on t-cell engaging immunotherapies, growing use of precision oncology treatments, expansion of targeted therapies for relapsed lymphomas, enhanced integration of biomarker-based patient selection.

The growing prevalence of blood cancers is expected to drive the growth of the Lunsumio market in the coming years. Blood cancer refers to cancers that affect the production and function of blood cells, typically originating in the bone marrow or lymphatic system. The most common types include leukemia, lymphoma, and myeloma. The rise in blood cancer cases can be attributed to factors such as an aging population, genetic predisposition, environmental exposures, weakened immune systems, lifestyle choices, and advancements in diagnostic techniques. Lunsumio (mosunetuzumab) is a bispecific antibody that helps treat blood cancers like lymphoma by targeting and binding to both cancerous B-cells and T-cells, allowing the immune system to eliminate cancer cells. It is particularly effective in managing diseases with a high prevalence of blood cancer, offering treatment options for patients with relapsed or refractory conditions. For example, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported that the number of leukemia cases increased to 62,770, up from 59,610 in 2023. Therefore, the rising prevalence of blood cancers is fueling the growth of the Lunsumio market.

A key trend in the Lunsumio market is the development of innovative approaches, including fixed-duration bispecific antibody therapies, to improve treatment effectiveness and expand patient access. Fixed-duration bispecific antibody therapies involve dual-targeting antibodies administered for a set period, rather than continuous dosing. This allows for effective disease control while reducing the long-term treatment burden. For example, in March 2025, Chugai Pharmaceutical, a Japan-based oncology/biotech company, launched Lunsumio for Intravenous Infusion (mosunetuzumab) for relapsed or refractory follicular lymphoma. This therapy is administered as monotherapy to patients who have failed two or more prior treatments, uses a predetermined treatment duration to reduce long-term treatment burden, and is designed to achieve high complete response rates and potentially durable remission in a difficult-to-treat patient population.

In October 2024, Lonza Group AG, a Switzerland-based manufacturing company that supplies pharmaceutical, healthcare, and life science products, acquired the Genentech manufacturing facility from Roche for $1.2 billion. With this acquisition, Lonza Group AG aims to expand its production capacity, enhance its technological capabilities, and solidify its position as a leading provider of contract development and manufacturing services for the biopharmaceutical industry. Roche Holding AG, a Switzerland-based pharmaceutical company, developed Lunsumio (mosunetuzumab) to treat relapsed or refractory follicular lymphoma.

Major companies operating in the lunsumio market are Roche Holding AG.

North America was the largest region in the lunsumio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lunsumio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lunsumio market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the lunsumio market by increasing costs of imported biologic raw materials, cell culture media, single-use bioprocessing systems, and cold-chain logistics components used in monoclonal and bispecific antibody manufacturing. North America and Europe are most affected due to reliance on globally sourced biologics inputs, while Asia-Pacific faces higher production and export-related compliance costs. These tariffs are contributing to higher manufacturing expenses and pricing pressures for advanced oncology therapies. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and investments in domestic biopharmaceutical production infrastructure.

The lunsumio market research report is one of a series of new reports that provides lunsumio market statistics, including lunsumio industry global market size, regional shares, competitors with a lunsumio market share, detailed lunsumio market segments, market trends and opportunities, and any further data you may need to thrive in the lunsumio industry. This lunsumio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lunsumio (mosunetuzumab) is a bispecific antibody used to treat relapsed or refractory follicular lymphoma. It targets CD20 on B-cells and CD3 on T-cells, enhancing immune system activity to attack cancer cells. Approved for patients who have not responded to previous treatments, Lunsumio offers a novel approach to cancer immunotherapy.

The primary formulations of Lunsumio are injectable (intravenous) and pre-filled syringes. Injectable intravenous (IV) formulations are designed for direct administration into the bloodstream, providing precise dosing and immediate therapeutic effects. This formulation is commonly used in clinical settings, especially for patients in critical conditions. It is indicated for treating relapsed or refractory follicular lymphoma (FL) and other non-Hodgkin lymphomas. Lunsumio is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is used by end users in hospitals, oncology clinics, specialty pharmacies, and research institutions.

The lunsumio market consists of sales of lunsumio (mosunetuzumab) 30 mg/30m, and lunsumio (mosunetuzumab -axgb) 1mh/ml. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.